Susanne Embleton - Pharming Group Investor Manager

Pharming Group Management Efficiency

The company has return on total asset (ROA) of (0.0125) % which means that it has lost $0.0125 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0501) %, meaning that it created substantial loss on money invested by shareholders. Pharming Group's management efficiency ratios could be used to measure how well Pharming Group manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/22/2025, Return On Tangible Assets is likely to drop to -0.03. In addition to that, Return On Capital Employed is likely to drop to -0.01. At this time, Pharming Group's Total Assets are relatively stable compared to the past year. As of 03/22/2025, Non Current Assets Total is likely to grow to about 176.9 M, while Intangible Assets are likely to drop slightly above 43.1 M.

Similar Executives

Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. Pharming Group N.V. is headquartered in Leiden, the Netherlands. Pharming Group operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 277 people. Pharming Group NV (PHAR) is traded on NASDAQ Exchange in USA. It is located in Darwinweg 24, Leiden, Netherlands, 2333 CR and employs 14 people. Pharming Group is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Pharming Group NV Leadership Team

Pharming Stock Performance Indicators

Additional Tools for Pharming Stock Analysis